← Back to headlines
Analysts Anticipate Upbeat Q2 for Johnson & Johnson Despite Stelara Headwinds
Analysts are forecasting a positive second-quarter earnings report for Johnson & Johnson, even as the company faces challenges related to its drug Stelara.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Recent Corporate Earnings Releases Highlight Divergent Financial Performance
29m ago
Markets Brace for Nvidia Earnings and Key PCE Inflation Data
30m ago
OpenAI’s Head of Data Centers Chris Malone Departs the Company
31m ago
Enbridge Acquires Salt Creek Midstream Crude Gathering Assets for $600 Million
37m ago